BRAF and melanoma: For predicting response to systemic therapy in high-stage melanomas, BRAF mutation status must be assessed, either using IHC specific for the V600E mutant protein or using BRAF gene mutation analysis before BRAF-inhibitor and MEK-inhibitor therapy can be initiated.